FSH therapy in male factor infertility: Evidence and factors which might predict the response
G Grande, A Graziani, R Scafa, A Garolla, D Santi… - Life, 2024 - pmc.ncbi.nlm.nih.gov
Follicle-stimulating hormone (FSH) administration is applied in the management of subjects
affected by hypogonadotropic hypogonadism. Whilst this application is widely recognized …
affected by hypogonadotropic hypogonadism. Whilst this application is widely recognized …
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial
A Ulys, F Jankevicus, M Jievaltas, R Venckus… - The …, 2024 - Wiley Online Library
Background Teverelix drug product (DP) is a novel injectable gonadotropin‐releasing
hormone antagonist. Methods An adaptive phase 2, open‐label, multicenter trial was …
hormone antagonist. Methods An adaptive phase 2, open‐label, multicenter trial was …
Impatto dei polimorfismi dei geni FSHB e FSHR in pazienti con sindrome di Klinefelter
R D'ANDREA - thesis.unipd.it
Abstract Introduction Klinefelter Syndrome (KS)(47, XXY) represents the most common
genetic cause of male infertility, characterized by a hypergonadotropic hypogonadism …
genetic cause of male infertility, characterized by a hypergonadotropic hypogonadism …